



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

FINNISH RED CROSS LICENSES GENEGO PRODUCTS

St. Joseph, MI. January 22nd, 2008 –GeneGo, Inc., the leading systems biology tools company, announced today that the Finnish Red Cross Blood Service has licensed GeneGo’s bioinformatics and cheminformatics suites MetaCore™ and MetaDrug™, respectively, to be used in a variety of research and clinical projects

“The entrepreneur knowledgebase behind the merged platform is impressive in the areas of cell adhesion and immunology, which is essential in blood transfusion field,” said docent Jukka Partanen, research director at the FRC Blood Service R&D.

In a joint effort with the Finnish hospitals, FRC Blood Service is collecting clinical information from nearly 70% of the patients receiving blood transfusions in the country, to optimize the blood component usage far beyond 2000 annual diagnoses. Beside the blood group and cell type analysis in disease and pregnancy, we are working with tissue typing of donors and recipients in organ, bone marrow and cord blood and bone marrow stem cell replacement transplantations.

“In the market, we have not found any other manually curated platform where multiple parallel omics data could be submitted in a batch mode in such a systems medicine fashion. We are delighted that the curation does not ignore the non-English journals and reviews patent literature as well. The principle of taking only causality and not mere association into account is critical in the era of NLP text mining servers and HTS data flood,” said Jukka Partanen.

“We are very pleased to be working with such a prestigious organization,” said Julie Bryant VP of Business development for GeneGo. “Disease-centric systems medicine is a natural and logical step in the development of our tools and databases and we are excited to see healthcare organizations such as Finnish Red Cross using it in such practical and important way.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of

different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

MetaCore™, MetaBase™, MetaDrug™, MetaLink™, MetaDiscovery™, MetaTox™, MetaMiner™ and 1-2-3 Workflow™ are trademarks of GeneGo, Inc.